RXRX (Recursion Pharmaceuticals) Research & Development: $433.53 Mil (TTM As of Mar. 2026)


RXRX Recursion Pharmaceuticals Inc RXRX
77 GF Score
Price $3.51
GF Value $4.15
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Recursion Pharmaceuticals Research & Development?

Recursion Pharmaceuticals RXRX +5.39% 77 Research & Development is $433.53 Mil as of Mar. 2026. GuruFocus rates RXRX with a GF Score™ of 77/100 and a GF Value™ of $4.15 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Recursion Pharmaceuticals's Research & Development for the three months ended in Mar. 2026 was $87.90 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $433.53 Mil.

Recursion Pharmaceuticals  (NAS:RXRX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Recursion Pharmaceuticals Research & Development Related Terms

Recursion Pharmaceuticals Research & Development Historical Data

* Premium members only.

The historical data trend for Recursion Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Recursion Pharmaceuticals Research & Development Chart

Recursion Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 135.27 155.70 241.23 314.42 475.27

Recursion Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 129.63 128.64 121.06 95.94 87.90
RXRX
77GF Score
Recursion Pharmaceuticals Inc RXRX
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Recursion Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $433.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $433.53 Mil mean?
Recursion Pharmaceuticals (RXRX) has a Research & Development of $433.53 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Recursion Pharmaceuticals and its competitors.
Is Recursion Pharmaceuticals' Research & Development too high?
Recursion Pharmaceuticals' current Research & Development is $433.53 Mil. Overall, Recursion Pharmaceuticals has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recursion Pharmaceuticals' Research & Development compare to RAPP and SRPT?
Recursion Pharmaceuticals' Research & Development of $433.53 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Recursion Pharmaceuticals and its competitors. Recursion Pharmaceuticals's current Research & Development is $433.53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recursion Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Recursion Pharmaceuticals (RXRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.15, compared to a current price of $3.51 — trading 15.4% below its estimated fair value. The current Research & Development is $433.53 Mil. Recursion Pharmaceuticals' overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Recursion Pharmaceuticals (RXRX), the current Research & Development is $433.53 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Recursion Pharmaceuticals (RXRX) Overvalued in 2026?

Based on GuruFocus' analysis, Recursion Pharmaceuticals stock appears to be undervalued. The current stock price of $3.51 is trading 15.4% below its estimated GF Value™ of $4.15. GuruFocus considers Recursion Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for RXRX:

  • Research & Development: $433.53 Mil
  • GF Value™: $4.15 vs. price of $3.51 (15.4% below fair value)
  • GF Score™: 77/100 with 4 warning signs

No single metric tells the full story. See the RXRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Recursion Pharmaceuticals Business Description

Other Exchanges RXRX:Mexico
Address 41 South Rio Grande Street, Salt Lake City, UT, USA, 84101
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
77GF Score

Get the complete analysis for RXRX

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.51
Price
$4.15
GF Value